Pediatrix Medical Group (NYSE:MD) Hits New 1-Year High – Here’s What Happened

Pediatrix Medical Group, Inc. (NYSE:MD) reached a new 52-week high during trading on Friday . The company traded as high as $12.99 and last traded at $12.91, with a volume of 352342 shares traded. The stock had previously closed at $12.67.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on MD shares. Jefferies Financial Group upgraded Pediatrix Medical Group from a “hold” rating to a “buy” rating and lifted their price objective for the company from $8.00 to $14.00 in a research report on Thursday, September 26th. UBS Group upped their price target on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research report on Friday, August 9th. StockNews.com upgraded shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research report on Wednesday, August 7th. Finally, Truist Financial boosted their target price on Pediatrix Medical Group from $10.00 to $13.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $10.90.

Pediatrix Medical Group Price Performance

The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.38 and a current ratio of 1.38. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -14.92, a PEG ratio of 1.84 and a beta of 1.56. The company has a fifty day simple moving average of $11.10 and a two-hundred day simple moving average of $9.14.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.03. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. The firm had revenue of $504.30 million during the quarter, compared to analyst estimates of $505.49 million. During the same quarter last year, the business earned $0.37 EPS. The company’s revenue was up .7% compared to the same quarter last year. As a group, equities research analysts expect that Pediatrix Medical Group, Inc. will post 1.19 earnings per share for the current fiscal year.

Insider Buying and Selling at Pediatrix Medical Group

In other news, Director Laura A. Linynsky sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the transaction, the director now owns 30,805 shares in the company, valued at $343,783.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO C Marc Richards sold 32,562 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $10.08, for a total transaction of $328,224.96. Following the completion of the transaction, the chief financial officer now owns 192,785 shares in the company, valued at $1,943,272.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Laura A. Linynsky sold 7,000 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the completion of the transaction, the director now directly owns 30,805 shares of the company’s stock, valued at $343,783.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 68,100 shares of company stock valued at $701,889. Corporate insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

Institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company raised its holdings in shares of Pediatrix Medical Group by 3.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company’s stock valued at $245,000 after purchasing an additional 1,088 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Pediatrix Medical Group by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 16,937 shares of the company’s stock worth $170,000 after buying an additional 1,167 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Pediatrix Medical Group by 47.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after buying an additional 1,524 shares during the period. SummerHaven Investment Management LLC grew its stake in Pediatrix Medical Group by 3.8% during the 2nd quarter. SummerHaven Investment Management LLC now owns 55,951 shares of the company’s stock worth $422,000 after purchasing an additional 2,069 shares in the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of Pediatrix Medical Group by 0.5% in the 2nd quarter. Bank of Montreal Can now owns 415,110 shares of the company’s stock valued at $3,196,000 after purchasing an additional 2,083 shares in the last quarter. 97.71% of the stock is owned by hedge funds and other institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.